Comparison · NCT04400058-b1129cf7
Octagam 10% vs Placebo: Cumulative Mortality Rate Through Day 33
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Octagam 10% vs Placebo: Cumulative Mortality Rate Through Day 33. Trial comparisons, record NCT04400058-b1129cf7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04400058-b1129cf7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.114 | 0.0666 | 0.189 | wilson | |
| Risk in group 2 | 0.0588 | 0.0272 | 0.122 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0555 | -0.024 | 0.137 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.94 | 0.758 | 4.98 | log | |
| Odds ratio, group 1 over group 2 | 2.06 | 0.744 | 5.73 | log | |
| Number needed to treat, for one more participant with the outcome on Octagam 10% than on Placebo | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Octagam 10% | Octagam 10%~Octagam 10%: Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days | 12 | 105 | OG000 |
| Group 2 | Placebo | Placebo~Placebo: Placebo | 6 | 102 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Cumulative Mortality Rate Through Day 33
- Description
- Cumulative mortality in subjects treated with Octagam 10% compared to those that received placebo at Day 33
- Time frame
- 33 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
- NCT number
- NCT04400058
- Phases
- PHASE3
- Conditions
- Covid-19
- Interventions
- Octagam 10%, Saline Solution
- Lead sponsor
- Octapharma
- Results first posted
- 2024-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04400058?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04400058-b1129cf7